Tumor cell motility: A novel therapeutic target in bladder carcinoma, experimental and clinical results

Advances in Experimental Medicine and Biology

Volumn 462, Issue , 1999, Pages 469-476

  Otto, T ^a   Lummen G ^a   Be, A ^a   Rubben H ^a   Raz, A ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOCRINE MOTILITY FACTOR RECEPTOR; CARBOPLATIN; PACLITAXEL; PERTUSSIS TOXIN;

ADULT; AGED; ANIMAL MODEL; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL ADHESION; CELL MOTILITY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0033281574     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4737-2_36     Document Type: Conference Paper

References (4)

1. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with carcinoma of the bladder
2. Limitations of M-VAC chemotherapy for the treatment of advanced bladder carcinomas
3. Improved prognosis assessment for patients with bladder cancer
4. Paclitaxel based second line therapy for patients with advanced chemotherapy -resistant bladder carcinoma (M1) - A clinical phase II study